- Biosimilars – Now a reality even for complex biologics
Biosimilars – Now a reality even for complex biologics
Tuesday 20 June 2017
Biosimilars: now a reality, even for complex biologics
Biosimilars have been a hot topic among healthcare investors for a few years now and should further take center stage over the next five years as eight out the Top 10 bestselling therapies worldwide will face biosimilar competition. Starting late but having all the relevant expertise and production know-how Biotech companies have partnered with large Pharmaceutical groups to develop biosimilars. While the BPCI Act within Obamacare set a regulatory framework for biosimilars to be approved by the US FDA, its different provisions had first to be battled in court for the law to take shape. This is now almost done.
Analysing the Exposure of Low-volatility Equity Strategies to Interest Rates
At the dawn of a potential rise in rates triggered by Central Banks in both Europe and the United States, doubts are being raised about the ability of low-volatility portfolios to continue to deliver robust performance.
CHINA: 19th party congress and beyond
"China’s economy appears to be more resilient than it was and the coming slowdown looks likely to be moderate."
The Bank of England raises rates: Bearish for the pound
The latest data indicate that the market is only slightly short GBP and we think that this view is too optimistic.